Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia

Wei Shen Tan; Simon Rodney; Benjamin Lamb; Mark Feneley; John Kelly

doi:10.1016/j.ctrv.2016.05.002

Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia

Cancer Treat Rev. 2016 Jun:47:22-31. doi: 10.1016/j.ctrv.2016.05.002. Epub 2016 May 10.

Authors

Wei Shen Tan¹, Simon Rodney², Benjamin Lamb³, Mark Feneley³, John Kelly²

Affiliations

¹ Division of Surgery and Interventional Science, University College London, 74 Huntley Street, London WC1E 6AU, UK; Department of Urology, University College London Hospital, 16-18 Westmoreland Street, London W1G 8PH, UK. Electronic address: wei.tan@ucl.ac.uk.
² Division of Surgery and Interventional Science, University College London, 74 Huntley Street, London WC1E 6AU, UK; Department of Urology, University College London Hospital, 16-18 Westmoreland Street, London W1G 8PH, UK.
³ Department of Urology, University College London Hospital, 16-18 Westmoreland Street, London W1G 8PH, UK.

PMID: 27231966
DOI: 10.1016/j.ctrv.2016.05.002

Abstract

Bladder cancer is the 8th most common cancer with 74,000 new cases in the United States in 2015. Non-muscle invasive bladder cancer (NMIBC) accounts for 75% of all bladder cancer cases. Transurethral resection and intravesical treatments remain the main treatment modality. Up to 31-78% of cases recur, hence the need for intensive treatment and surveillance protocols which makes bladder cancer one of the most expensive cancers to manage. The purpose of this review is to compare contemporary guidelines from Europe, (European Association of Urology), the United States (National Comprehensive Cancer Network), the United Kingdom (National Institute for Health and Care Excellence), Japan (Japanese Urological Association) and the International Consultation on Bladder Cancer (ICUD). We compare and contrast the different guidelines and the evidence on which their recommendations are based.

Keywords: Bladder cancer; Consensus guidelines; Non-muscle invasive bladder cancer; Recommendations; Review.

Publication types

Review

MeSH terms

Humans
Medical Oncology / methods*
Medical Oncology / standards*
Practice Guidelines as Topic
Urinary Bladder Neoplasms / diagnosis*
Urinary Bladder Neoplasms / therapy*

Abstract

Publication types

MeSH terms

Grants and funding